Get the Stockscreener App
52.57
0.10%
-0.05
After Hours:
52.33
-0.24
-0.46%
Soleno Therapeutics Inc stock is traded at $52.57, with a volume of 5.20M.
It is down -0.10% in the last 24 hours and up +55.74% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$52.62
Open:
$52.64
24h Volume:
5.20M
Relative Volume:
1.66
Market Cap:
$2.72B
Revenue:
$190.41M
Net Income/Loss:
$20.48M
P/E Ratio:
235.95
EPS:
0.2228
Net Cash Flow:
$46.66M
1W Performance:
-0.06%
1M Performance:
+55.74%
6M Performance:
-22.31%
1Y Performance:
-25.17%
1-Day Range:
$52.56
$52.68
1-Week Range:
$52.41
$52.69
52-Week Range:
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.57 | 2.72B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR DEADLINE: Soleno Therapeutics, Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead the Soleno Class Action Lawsuit- Hagens Berman - Barchart.com
Halper Sadeh LLC is Investigating Whether AVNS, LEG, SLNO, FORA are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky - PR Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - TMX Newsfile
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Soleno Therapeutics Investors Seek Lead Plaintiff in Class Action - National Today
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman - PR Newswire
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities - GlobeNewswire
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Neurocrine Acquires Soleno for $2.9B - San Diego Business Journal
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Trading the Move, Not the Narrative: (SLNO) Edition - Stock Traders Daily
2026-04-12 | SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - NewMediaWire
FinancialContentNASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - FinancialContent
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
SLNO Shareholder Alert: Soleno Therapeutics, Inc. - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Sahm
TD Cowen Downgrades Soleno Therapeutics to 'Hold' - National Today
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SLNO DEADLINE NOTICE: Soleno Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 5, 2026 - ACCESS Newswire
Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors with ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Subst - GuruFocus
SLNO Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit - National Today
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein - GlobeNewswire
Soleno Therapeutics Downgraded to 'Hold' by Cantor Fitzgerald - National Today
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):